Education

1978-1982 Shanghai University, B.S.

1989-1995 Biochemistry and Molecular Biology from the University of Texas Health Science Center, Ph.D.

Academic Experience

1995/9-2000/8 UCSF, Gladstone Institute of Virology & Immunology, Postdoc

2000/9-2004/8 SUNY School of Medicine, Buffalo, Assistant Professor

2004/9-2016/12 University of Texas, MD Anderson Cancer Center, Associate Professor, Professor, Endowed Professor

2010/9-2014/8 University of Texas, MD Anderson Cancer Center, Center for Inflammation and Cancer, Associate Director

2012/9-2014/8 University of Texas, Graduate School of Biomedical Sciences, Cancer Biology Program, Director

2014/10-now Tsinghua University, School of Medicine, Department of Basic Medical Sciences, Professor and Chairman

Overview of Academic Research

1、Adoptive T cell immunotherapy;

2、Molecular mechanisms of innate immune response;

3、Regulation mechanisms of T cell activation.

Major Honor and Awards

Endowed chair professor in University of Texas MD Anderson Cancer Hospital

University of Texas MD Anderson Cancer Hospital Scholars Program

Leukemia & Lymphoma Society of America Scholars Program

American Institute for Cancer Research Investigator Award

The Organization Department of the CPC Central Committee

Cheung Kong Lecture Professorship

2020 Tsinghua-Bayer Chair Professor

Representative Research Achievements

1.   Xu X, Xu J, Zheng G, Lu H, Rui W, Guan J, Cheng L, Yang D, Wang M, Duan J, Lv Q, Li J, Zhao X, Chen C, Shi P, Jia X*, Lin X*. (2018). CARD9S12N mutation converts alveolar macrophages into IL-5-producing cells and facilitates type 2 immune responses. Nature Immunology, 2018 Jun;19(6):547-560. 

2.   Wang M, Zhang S, Zheng G, Huang J, Songyang Z, Zhao X, Lin X. (2018). Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A. Immunity. 2018 Jul 17;49(1):66-79

3.   Wang T, Fan C, Yao A, Xu X, Zheng G, You Y, Jiang C, Zhao X, Hung MC, Lin X. (2018). The adaptor protein CARD9 protects against colitis-associated colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells. Immunity, 2018 Sep 18;49(3):504-514

4.   Yang D, Zhao X, Lin X (2019) Bcl10 is required for the development and suppressive function of Foxp3+ regulatory T cells. Cell Mol Immunol. 2019.

5.   Tang Y, Tu H, Zhang J, Zhao X, Lin X (2019). K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation. Nat Commun. 2019 Sep 13;10(1):4157. 

6.   Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, Dong J, Zhao X, and Lin X (2020) CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Euro J Immunol. 2020 Jan 24.

7.   Yue Liu*, Guangna Liu*, Jiashang Wang*, Zhe-yu Zheng , Lemei Jia, Wei Rui, Liqun Zhou, Xin Wu, Song Lin, Xueqiang Zhao, Xin Lin, Chimeric STAR Receptors Using TCR Machinery Mediate Robust Responses Against Solid Tumors, Science Translational Medicine, 13, eabb5191, 2021

8.   A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia，作者：Wang, Jiasheng; Zhang, Xian; Zhou, Zhixiao; Liu, Yue; Yu, Li; Jia, Lemei; Yang, Junfang; Li, Jingjing; Yu, Hanyang; Li, Wenzhong; Liu, Guangna; Rui, Wei; Zheng, Hongli; Zhao, Xueqiang; Lin, Xin; Lu, Peihua. American Journal of Hematology, 2022, 97(8), 992-1004.

9.   Tyrosine phosphorylation regulates RIPK 1 activity to limit cell death and inflammation. Hailin Tu, Weihang Xiong, Jie Zhang, Xueqiang Zhao, Xin Lin. Nature Communications. 13, 6603 (2022).